Skip to main content
Clinical Trials/NCT03107143
NCT03107143UnknownNot Applicable

A Randomized, Non-blind Study of TurnCare's Q-2 System on the Sacral Pressure Ulcer Prevention in High Risk Patients at St. Vincent's Medical Center

TurnCare Inc.0 sites431 target enrollmentStarted: June 15, 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
431
Primary Endpoint
Incidence of hospital acquired sacral region pressure ulcers in treatment and control groups.

Study Overview

Brief Summary

This is a non-blind randomized clinical trial to determine the efficacy of the TurnCare Q2 System for the prevention of sacral region (sacral, coccygeal, and buttocks) pressure ulcers. TurnCare Q2 System has 2 main components: 1. An Inflatable Skin Perfusion Enhancement Surface and 2. An Adaptive Pressure Controller. The Skin Perfusion Enhancement Surface has a patented design that accommodate human anatomy in the sacra region. The Adaptive Pressure Controller is powered by APSAR technology that provides patient specific pressure relieve in the sacral region.

Detailed Description

This study is a prospective, non-blinded randomized clinical trial. The study protocol and the consent form were approved by the IRB at the study institution. Consecutive adult patients admitted to the hospital with Braden Scale scores of 16 or less who did not meet exclusion criteria were consented and enrolled in the study. All in-patients were either scheduled admissions or were admitted through the emergency department. Upon admission, risk assessments for pressure ulcers and total body surveys were performed by the hospital staff. A Braden Scale score was determined for each patient by the hospital staff according to standard hospital protocol. Both the control group and the treatment group patients received standard care for pressure ulcer prevention according to hospital protocols, policies and guidelines. Standard pressure ulcer prevention measures for this facility include a methodology referred to as a "S.K.I.N." Bundle (S-surface selection, K-keep turning, I-incontinence management, N-nutrition.) This successful pressure ulcer prevention initiative was developed within the parent health organization and standardized throughout its 131 hospitals. In accordance with the S.K.I.N. Bundle, all patients admitted to the study hospital were repositioned every two hours, provided incontinence care, and given aggressive nutritional management as indicated. All care measures were documented in the hospital's electronic medical record (EMR) system. After obtaining informed consents, patients in the treatment group had the Q2 System placed on their beds and chairs. Perfusion enhancement surfaces were placed directly on hospital beds under the fitted bed sheets and were secured to bed frames with disposable Velcro straps. A disposable "chux" pad and lifter sheet were placed on top of the fitted sheets as is standard in most hospital settings. Adaptive pressure controllers were secured to bed footboards or attached to bases of IV poles. Specific settings for each patient were entered into the controllers. The controller settings entered included patient body weight and bed position (degrees of incline). The bed position included a bed setting (30 degrees incline) and a chair setting (90 degrees incline). When applicable, a second perfusion enhancement surface was placed on a hospital chair so that the Q2 solution could be utilized in a "sitting mode" while patients were sitting in hospital chairs. The Q2 Systems remained in continuous operation during the trial period. Patient skin did not contact any part of the Q2 system directly at any time.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects have a Braden Score of 16 or less without pre-existing sacral region pressure ulcers and are not subject to

Exclusion Criteria

  • •Exclusion Criteria:
  • •Pre-existing sacral region pressure ulcer
  • •Refusal to participate
  • •Inability to obtain consent
  • •Pregnancy
  • •Age less than 18 years
  • •Mentally challenged
  • •Unstable spine or pelvic injuries
  • •Recent surgical skin graft to sacral area
  • •Weight > 400 lbs.
  • •Psychiatric condition

Arms & Interventions

Treatment Group

Experimental

Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.

Intervention: Q2 System (Device)

Control Group

No Intervention

Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System

Outcomes

Primary Outcomes

Incidence of hospital acquired sacral region pressure ulcers in treatment and control groups.

Time Frame: Up to 10 weeks. Average of 4 weeks from enrollment.

Rate of hospital acquired sacral pressure ulcer occurrence measurred in metrics named "number of incidences in 1,000 patient days."

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
TurnCare Inc.
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Completed
Phase 2
Efficacy of a new COVID-19 treatmentCOVID-19
PACTR202006899597082Malagasy government60
Completed
Phase 2
A Phase 2 Double -blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of 10 mcg HXP-GPOVac Vaccine in Healthy Volunteershealthy adultsphase 2, covid vaccine, clinical trial, HXP-GPOVac
TCTR20220819003Government Pharmaceutical Organization, Thailand300
Active, not recruiting
Not Applicable
Clinical trial to determinate viral load in seminal fluid in HIV-positive patients without previous treatmentHIV-1 infectionMedDRA version: 17.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2014-001348-39-ESFundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI)
Active, not recruiting
Phase 1
Phase II trial testing Ablative radiotherapy in metastatic prostatecancer, resistant to hormonal therapy and with number of metastatic lesions lower or equal to three.Oligometastatic prostate cancer, castration resistantMedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-005284-13-ITDIPARTIMENTO DI SCIENZE BIOMEDICHE SPERIMENTALI E CLINICHE, UNIVERSITà DI FIRENZE174
Not yet recruiting
Phase 2
A Clinical trial to study the effect of SDLSNT21 tablet in Patients of Nidranash(Insomnia).
CTRI/2023/02/049355Dean Faculty of Ayurved